This website uses cookies. By using the site you are agreeing to our Privacy Policy.


HOME >> Investor Relations >> Top Message

PRINT

To Our Investors

Thank you for attending our Annual General Shareholders Meeting and Business Briefing on June 25th.
I am glad to have had the opportunity to directly receive feedback from you.We have received a very meaningful time, asking for your feedback through many questions.

Enhance synergy with Fujifilm Group under the new management system

President and CEO Ken-ichiro Hata
President & CEO
Ken-ichiro Hata

Our company has established a new management system and is about to move forward more rapidly toward the development of its business enterprises.

As indicated in the mid-term business plan, the activities that should be given special focus this year are the construction of an innovative production system for regenerative medicine products and others and the strengthening of our selling power. After the completion of the numerous product development projects we are now working on, it will be necessary to provide products to a number of patients that is incomparably greater than before. We must achieve more stable production at a lower cost. Moreover, the number of doctors who use our products will increase. It will be important to provide information appropriately so that they can use our products properly. In addition to our experience manufacturing and marketing of the “Autologous Cultured Epidermis JACE” and “Autologous Cultured Cartilage JACC” cultivated over the past 20 years, we would like to make full use of FUJIFILM’s production technology and medical device marketing know-how to rapidly find solutions to these challenges.

I was recently appointed as Chairperson and Representative Director of the “The Forum for Innovative Regenerative Medicine”, an organization of corporations in the regenerative medicine field. This organization with over 240 corporate members includes many prominent corporations. In order to truly transform regenerative medicine into an industry and promote the widespread adoption of these products, cooperation with all of these fellow corporations will be extremely important. Through these efforts we would like to strive to establish the necessary system and environment to make regenerative medicine an industry.

June 26, 2019
President & CEO Ken-ichiro Hata
President & CEO
Japan Tissue Engineering Co., Ltd.

Message from the New President and COO of J-TEC

President & COO Masataka Akiyama
President & COO
Masataka Akiyama

I am Masataka Akiyama, recently appointed as the President and COO of Japan Tissue Engineering Co., Ltd. (J-TEC). I would like to say a few words of greeting upon my appointment as the President.

After joining FUJIFILM (at that time, Fuji Photo Film Co., Ltd.,) in 1988, I was involved in the graphic system business and medical system business, and while posted to the United States, I experienced the rapid expansion of the medical IT market that was set in motion by Obamacare. Since 2018, I have been involved in regenerative medicine as the Director of the Regenerative Medicine Department.

Regenerative medicine is about to undergo major changes with the advent of cell therapies using the new gene editing technology, among others. Just as FUJIFILM overcame the wave of digitalization to go on growing, J-TEC aims to be a corporation that does not stop at appropriately responding to changes in the business environment but proactively brings about change itself in order to continue growing.

In the days ahead, I will work together with all of the employees to promote the further spread of regenerative medicine by developing and marketing products and services that provide new value. I will devote myself to making efforts to meet the expectations of all of you, so I ask for your guidance and encouragement.


June 26, 2019
President & COO Masataka Akiyama
President & COO
Japan Tissue Engineering Co., Ltd.